Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma
- 1 October 2018
- journal article
- letter
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 13 (10) , e204-e206
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancerNature Medicine, 2018
- In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerOncotarget, 2015
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6The Lancet Oncology, 2015
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerScience Translational Medicine, 2013
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implicationsThe Lancet Oncology, 2012